Please login to the form below

Not currently logged in
Email:
Password:

Lumena Pharmaceuticals

This page shows the latest Lumena Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Silver lining as Shire rare disease programme hits a setback

Silver lining as Shire rare disease programme hits a setback

The drug candidate had been tipped by some analysts as a blockbuster and was the most advanced asset acquired as part of Shire's $260m-plus purchase of Lumena Pharmaceuticals last

Latest news

  • The moving parts of orphan drug development The moving parts of orphan drug development

    And in May Shire agreed a pipeline-boosting deal to buy US company Lumena Pharmaceuticals for upwards of $260m. ... The acquisition of Lumena certainly ties in perfectly with Shire's recent escalation of its activities in rare diseases, which has been

  • Shire boosts rare disease portfolio with $260m Lumena deal Shire boosts rare disease portfolio with $260m Lumena deal

    Shire boosts rare disease portfolio with $260m Lumena deal. Acquisition of US company will bring two mid-stage candidates for rare liver diseases. ... Shire has agreed a deal to buy US company Lumena Pharmaceuticals for upwards of $260m, bolstering its

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    One company with an uneasy mixture of pharmaceuticals and consumer products is Reckitt Benckiser. ... Shire also continues with its well-established strategy to develop and market products for treating rare diseases with its acquisition of the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics